Cargando…

Selective arterial embolization of renal angiomyolipomas: A 10‐year experience

OBJECTIVES: To study safety and efficacy of selective endovascular trans‐arterial embolization (TAE) of renal angiomyolipoma (AML) in a 10‐year period at a regional tertiary referral center in Denmark. PATIENTS AND METHODS: All 56 patients who underwent TAE of renal AML at Departments of Urology and...

Descripción completa

Detalles Bibliográficos
Autores principales: Nozadze, Guram, Larsen, Signe Benzon, Heerwagen, Søren, Juhl Jensen, Ruben, Lönn, Lars, Røder, Martin Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988688/
https://www.ncbi.nlm.nih.gov/pubmed/35475158
http://dx.doi.org/10.1002/bco2.107
_version_ 1784683018264248320
author Nozadze, Guram
Larsen, Signe Benzon
Heerwagen, Søren
Juhl Jensen, Ruben
Lönn, Lars
Røder, Martin Andreas
author_facet Nozadze, Guram
Larsen, Signe Benzon
Heerwagen, Søren
Juhl Jensen, Ruben
Lönn, Lars
Røder, Martin Andreas
author_sort Nozadze, Guram
collection PubMed
description OBJECTIVES: To study safety and efficacy of selective endovascular trans‐arterial embolization (TAE) of renal angiomyolipoma (AML) in a 10‐year period at a regional tertiary referral center in Denmark. PATIENTS AND METHODS: All 56 patients who underwent TAE of renal AML at Departments of Urology and Radiology, Copenhagen University Hospital – Rigshospitalet, Denmark, from 2009 to 2020 were included. Seven without preoperative and postoperative imaging were excluded, leaving 49 patients for analysis. From national electronic medical records, we retrieved patient characteristics, surgical data, and follow‐up data. Tumor size at the time of embolization and during follow‐up was compared using Student's paired t test. Estimated glomerular filtration rate (eGFR) pre‐ and post‐embolization were compared using Wilcoxon rank sum test. RESULTS: We included 49 patients of whom 4 had two tumors treated in the same TAE procedure. Median age was 50 years (interquartile range [IQR]: [29–67 years]), and the median follow‐up time was 4.6 years [IQR: 3.0–6.7 years]. Post‐embolization syndrome (PES) was experienced in 27 patients, and non‐PES in 5 patients. Median length of hospital stay was 0 days [IQR, 0–1]. Postoperative Everolimus immunosuppressive treatment was offered to seven patients. Median tumor size was 6.0 cm [IQR: 4.6–7.9 cm] and was significantly reduced to 3.7 cm [IQR: 2.5–5.2 cm] after treatment (p < 0.001). Kidney function was not affected by TAE. Three deaths, not related to AML, were noted during follow‐up. CONCLUSION: Embolization of AML was in this cohort effective to significantly reduce tumor size without serious adverse events and loss of renal function. TAE is a safe and efficacious treatment and the preferred minimally invasive treatment option of AML.
format Online
Article
Text
id pubmed-8988688
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89886882022-04-25 Selective arterial embolization of renal angiomyolipomas: A 10‐year experience Nozadze, Guram Larsen, Signe Benzon Heerwagen, Søren Juhl Jensen, Ruben Lönn, Lars Røder, Martin Andreas BJUI Compass Original Articles OBJECTIVES: To study safety and efficacy of selective endovascular trans‐arterial embolization (TAE) of renal angiomyolipoma (AML) in a 10‐year period at a regional tertiary referral center in Denmark. PATIENTS AND METHODS: All 56 patients who underwent TAE of renal AML at Departments of Urology and Radiology, Copenhagen University Hospital – Rigshospitalet, Denmark, from 2009 to 2020 were included. Seven without preoperative and postoperative imaging were excluded, leaving 49 patients for analysis. From national electronic medical records, we retrieved patient characteristics, surgical data, and follow‐up data. Tumor size at the time of embolization and during follow‐up was compared using Student's paired t test. Estimated glomerular filtration rate (eGFR) pre‐ and post‐embolization were compared using Wilcoxon rank sum test. RESULTS: We included 49 patients of whom 4 had two tumors treated in the same TAE procedure. Median age was 50 years (interquartile range [IQR]: [29–67 years]), and the median follow‐up time was 4.6 years [IQR: 3.0–6.7 years]. Post‐embolization syndrome (PES) was experienced in 27 patients, and non‐PES in 5 patients. Median length of hospital stay was 0 days [IQR, 0–1]. Postoperative Everolimus immunosuppressive treatment was offered to seven patients. Median tumor size was 6.0 cm [IQR: 4.6–7.9 cm] and was significantly reduced to 3.7 cm [IQR: 2.5–5.2 cm] after treatment (p < 0.001). Kidney function was not affected by TAE. Three deaths, not related to AML, were noted during follow‐up. CONCLUSION: Embolization of AML was in this cohort effective to significantly reduce tumor size without serious adverse events and loss of renal function. TAE is a safe and efficacious treatment and the preferred minimally invasive treatment option of AML. John Wiley and Sons Inc. 2021-08-31 /pmc/articles/PMC8988688/ /pubmed/35475158 http://dx.doi.org/10.1002/bco2.107 Text en © 2021 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Nozadze, Guram
Larsen, Signe Benzon
Heerwagen, Søren
Juhl Jensen, Ruben
Lönn, Lars
Røder, Martin Andreas
Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title_full Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title_fullStr Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title_full_unstemmed Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title_short Selective arterial embolization of renal angiomyolipomas: A 10‐year experience
title_sort selective arterial embolization of renal angiomyolipomas: a 10‐year experience
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988688/
https://www.ncbi.nlm.nih.gov/pubmed/35475158
http://dx.doi.org/10.1002/bco2.107
work_keys_str_mv AT nozadzeguram selectivearterialembolizationofrenalangiomyolipomasa10yearexperience
AT larsensignebenzon selectivearterialembolizationofrenalangiomyolipomasa10yearexperience
AT heerwagensøren selectivearterialembolizationofrenalangiomyolipomasa10yearexperience
AT juhljensenruben selectivearterialembolizationofrenalangiomyolipomasa10yearexperience
AT lonnlars selectivearterialembolizationofrenalangiomyolipomasa10yearexperience
AT rødermartinandreas selectivearterialembolizationofrenalangiomyolipomasa10yearexperience